3M Drug Delivery Systems has announced an expansion of its pressurized metered dose inhaler (pMDI) manufacturing capacity at its Northridge, CA facility. The company is adding a pressure fill line to the existing cold fill line in the Northridge facility, which is one of four 3MDDS MDI filling sites worldwide. The company also announced the establishment of a … [Read more...] about 3MDDS expands pMDI manufacturing capacity
News
Freeman Technology wins Queen’s Award for Enterprise
Freeman Technology has won a 2012 Queen’s Award for Enterprise in the category of International Trade. The company previously won a Queen’s Award in the category of Innovation for its powder characterization technology. Managing Director Tim Freeman commented, "Freeman Technology’s first Queen’s Award in 2007 celebrated our development of the FT4 Powder Rheometer … [Read more...] about Freeman Technology wins Queen’s Award for Enterprise
CHMP issues positive opinion on flutiform
The EMA's Committee for Medicinal Products for Human Use ("CHMP") has issued a positive opinion on SkyePharma's MAA for its flutiform fluticasone propionate/formoterol fumarate MDI for the treatment of asthma. The MAA had been referred to CHMP after the concerned member states failed to reach consensus on the application. According to SkyePharma, the company … [Read more...] about CHMP issues positive opinion on flutiform
Synairgen announces positive Phase 2 results for inhaled interferon beta
UK-based Synairgen has announced positive data from a Phase 2 trial of its SNG001 inhaled interferon beta as protection against the common cold and other respiratory viral infections in asthma patients. According to the company, SNG001 showed statistically significant improvements compared to placebo in prevention of symptom worsening during the first week of … [Read more...] about Synairgen announces positive Phase 2 results for inhaled interferon beta
Mylan expands respiratory capabilities in Ireland
Mylan has announced that it will invest up to $100 million annually over a five-year period to add a total of 500 new jobs to its work forces in Dublin and Galway, Ireland by 2016. The investment includes funding for R&D and manufacturing in solid dose and injectables in addition to the respiratory area. Mylan currently employs approximately 700 people in Ireland at … [Read more...] about Mylan expands respiratory capabilities in Ireland
FivePrime to discover asthma/COPD compounds for GSK
Biologics discovery company Five Prime Therapeutics has announced a deal with GlaxoSmithKline giving GSK "exclusive access to FivePrime’s drug discovery platforms in up to six programs to identify first-in-class agents and new mechanisms relevant to refractory asthma and chronic obstructive pulmonary disease (COPD)." This is the second discovery deal between the two … [Read more...] about FivePrime to discover asthma/COPD compounds for GSK
MAP gets new patent for Levadex, schedules meeting with FDA
MAP Pharmaceuticals has announced that it has a meeting scheduled with the FDA during the second quarter of this year to discuss the complete response letter it received for its Levadex inhaled dihydroergotamine application. MAP President and CEO Timothy S. Nelson said, "We are pleased that the FDA has scheduled a meeting with us to discuss the issues contained in the … [Read more...] about MAP gets new patent for Levadex, schedules meeting with FDA
US company introduces OTC horseradish nasal spray
Over-the-counter drug manufacturer GSC Products has introduced a horseradish nasal spray marketed as "Sinus Plumber." The company also developed a capsaicin nasal spray called Sinus Buster that was acquired by Hi-Tech Pharmacal earlier this year and a caffeinated nasal spray called Turbo Snort. Sinus Plumber, which the company is marketing as a cure for allergy … [Read more...] about US company introduces OTC horseradish nasal spray
SkyePharma announces second inhaler study with Respivert
SkyePharma has signed an agreement with RespiVert for a feasibility study to develop an inhaled dry powder formulation for a RespiVert compound, the second DPI project that the two companies have worked on together. Both projects involve the devlopment of inhaled drugs for the treatment of COPD and asthma. SkyePharma CEO Peter Grant commented, “We are pleased that … [Read more...] about SkyePharma announces second inhaler study with Respivert
Winston gets grant for development of nasal spray for trigeminal neuralgia
The National Institutes of Health (NIH) has awarded Winston Pharmaceuticals a $375,000 Small Business Innovation Research (SBIR) grant to support Phase 1 development of its civamide nasal spray for the treatment of postherpetic neuralgia (PHN) of the trigeminal nerve (TN). Civamide is a proprietary TRPV-1 receptor modulator that previously received orphan drug … [Read more...] about Winston gets grant for development of nasal spray for trigeminal neuralgia